Affirm Holdings, Inc.

**Signal Note: Driehaus Capital Initiates AFRM Position** This move is notable primarily as a portfolio rebalancing signal rather than a biotech-specific catalyst—Affirm is a fintech/BNPL platform with no direct drug development pipeline. Driehaus's $16.2M entry suggests conviction in AFRM's operational inflection or valuation reset, but this falls outside traditional biotech thesis and doesn't indicate emerging clinical data or pipeline advancement in any therapeutic area.